Today, we will see why Intercept Pharmaceuticals (ICPT) can be an attractive albeit high-risk pick in 2020.
Company overview
Intercept Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies targeting progressive non-viral liver diseases. The targeted conditions include PBC (Primary Biliary Cholangitis), NASH (Nonalcoholic steatohepatitis), PSC (Primary Sclerosing Cholangitis), and biliary atresia. The company’s lead asset, farnesoid X receptor agonist, Ocaliva (obeticholic acid) in combination with ursodeoxycholic acid, is already approved by the FDA in PBC indication. The company was founded in 2002 and went public in October 2012.